CSL wins $230 million H1N1 vaccine order
Monday, 01 June, 2009
CSL's US subsidiary, CSL Biotherapies, has signed a $230 million (USD180 million) contract with the US Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine in bulk form.
CSL has also announced it will supply the Novel A (H1N1) vaccine to Australia.
The vaccine will be manufacturered at CSL's facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts.
The new vccine will be tested in clinical trials funded by HHS.
CSL has declared that it will maintain its committment to supply seasonal influenza vaccines to Australia, the US and other markets.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
